Last reviewed · How we verify
NMD670
At a glance
| Generic name | NMD670 |
|---|---|
| Sponsor | NMD Pharma A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis (PHASE2)
- Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy (PHASE2)
- Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMD670 CI brief — competitive landscape report
- NMD670 updates RSS · CI watch RSS
- NMD Pharma A/S portfolio CI